Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
CDKL1 N/A
Sequence Length (AA) Molecular Weight (Da)
358 41803
Protein Name
Cyclin-dependent kinase-like 1
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MMEKYEKIGK IGEGSYGVVF KCRNRDTGQI VAIKKFLESE DDPVIKKIAL
60 70 80 90 100
REIRMLKQLK HPNLVNLLEV FRRKRRLHLV FEYCDHTVLH ELDRYQRGVP
110 120 130 140 150
EHLVKSITWQ TLQAVNFCHK HNCIHRDVKP ENILITKHSV IKLCDFGFAR
160 170 180 190 200
LLAGPSDYYT DYVATRWYRS PELLVGDTQY GPPVDVWAIG CVFAELLSGV
210 220 230 240 250
PLWPGKSDVD QLYLIRKTLG DLIPRHQQVF STNQYFSGVK IPDPEDMEPL
260 270 280 290 300
ELKFPNISYP ALGLLKGCLH MDPTQRLTCE QLLHHPYFEN IREIEDLAKE
310 320 330 340 350
HNKPTRKTLR KSRKHHCFTE TSKLQYLPQL TGSSILPALD NKKYYCDTKK
358
LNYRFPNI

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for non-CPTAC-6019 Collapse assay details

Data source: Panorama

Official Gene Symbol
CDKL1
Peptide Sequence
FLESEDDPVIK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
36
Peptide End
46
CPTAC ID
non-CPTAC-6019
Peptide Molecular Mass
1,290.6343
Species
Human
Assay Type
Direct PRM
Matrix
SUM159 tryptic digest
Submitting Laboratory
Washington University in St. Louis
Submitting Lab PI
Reid Townsend

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Q-Exactive
Internal Standard
25fmol
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
EASY-nLC 1000
Column Packing
C18
Column Dimensions
75 µm x 50 cm
Flow Rate
300nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y9 (1+) 4.4 2.4 2 4.9 3.9 2.4 6.6 4.6 3.1 15 15 15
y8 (1+) 3.9 2.8 1.6 4.7 4.5 2.7 6.1 5.3 3.1 15 15 15
y4 (1+) 2.4 2.2 0.9 2.4 4.5 3.1 3.4 5 3.2 15 15 15
sum 2 2.1 0.9 1.9 4.2 2.5 2.8 4.7 2.7 15 15 15


Additional Resources and Comments


Assay Details for non-CPTAC-6018 Collapse assay details

Data source: Panorama

Official Gene Symbol
CDKL1
Peptide Sequence
IGEGSYGVVFK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
11
Peptide End
21
CPTAC ID
non-CPTAC-6018
Peptide Molecular Mass
1,154.5972
Species
Human
Assay Type
Direct PRM
Matrix
SUM159 tryptic digest
Submitting Laboratory
Washington University in St. Louis
Submitting Lab PI
Reid Townsend

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Q-Exactive
Internal Standard
25fmol
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
EASY-nLC 1000
Column Packing
C18
Column Dimensions
75 µm x 50 cm
Flow Rate
300nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y5 (1+) 4.2 4 3.9 3.7 4.2 3.3 5.6 5.8 5.1 15 15 15
y8 (1+) 7.8 4.2 4.3 7 3.8 5 10.5 5.7 6.6 15 15 15
y3 (1+) 4.4 5.2 3.7 5.8 3.4 4 7.3 6.2 5.4 15 15 15
sum 3.5 3.9 3.2 3.7 3.1 3.2 5.1 5 4.5 15 15 15


Additional Resources and Comments